or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    EXEL B 0.07 6.44
    RVMD B -0.11 5.78
    GILD B 1.16 5.73
    INCY C -1.29 5.36
    BGNE D -0.40 5.04
    ACLX C 0.81 4.42
    SRPT F -0.42 3.64
    REGN F 0.60 3.22
    MRK F 1.93 2.97
    TWST F 2.53 2.77
    SWTX C -2.40 2.39
    IOVA F 1.35 2.38
    BEAM D -2.12 2.36
    LGND C 4.72 2.33
    GERN C 0.38 2.18
    DVAX C 2.10 1.93
    BCRX D 1.99 1.70
    NRIX C 0.77 1.69
    BPMC C 2.40 1.46
    NVAX F 0.56 1.24
    MRNA F 1.94 1.13
    CRSP D -2.16 1.01
    VIR F 0.61 0.90
    RCUS F -1.95 0.88
    IBRX C 2.87 0.84
    ARCT F 5.88 0.53
    OABI D 0.51 0.47
    NTLA F 6.90 0.39
    FDMT F -4.76 0.38
    XNCR B 1.10 0.35
    QURE D 2.89 0.35
    DNA F 3.46 0.32
    EDIT F -1.84 0.28
    MGNX D -1.98 0.26

    Represented by ETF Holdings

    Keywords: Biotechnology Biopharmaceutical Cancer Medicine Biology Life Sciences Immune System Infectious Diseases Monoclonal Antibodies Antibodies Clinical Development Clinical Medicine Coronavirus Genetics Immunology Influenza S&P 500 Cancer Treatment Enzymes Nasdaq 100
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research

    Recent News for iShares Genomics Immunology and Healthcare ETF & its Holdings

    Date Stock Title
    Nov 21 INCY Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
    Nov 21 MRK Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference
    Nov 21 MRNA Major companies that are also popular short-selling stocks
    Nov 21 QURE uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
    Nov 21 MRK Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
    Nov 21 MRK Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
    Nov 21 CRSP CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
    Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Nov 20 MRNA CDC warns of an imminent spike in COVID, flu cases
    Nov 20 MRK Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
    Nov 20 MRK Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
    Nov 20 SWTX SpringWorks started at outperform by Evercore ahead of FDA decision
    Nov 20 NVAX Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)
    Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
    Nov 20 CRSP CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
    Nov 20 IBRX High Growth Tech Stocks To Watch In November 2024
    Nov 20 TWST Twist Bioscience Full Year 2024 Earnings: EPS Misses Expectations
    Nov 20 MRNA Moderna initiated with a Hold at Berenberg
    Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
    Nov 20 TWST Twist Bioscience price target lowered to $52 from $55 at Barclays
    The investment seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma Index. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
    Exchange Traded Fund Immunology Genomics
    Back to the Main IDNA Page...